Digestive Diseases and Sciences

, Volume 56, Issue 1, pp 131–138

Bax Predicts Outcome in Gastric Cancer Patients Treated with 5-fluorouracil, Leucovorin, and Oxaliplatin Palliative Chemotherapy

  • Seong Hyun Jeong
  • Jae Ho Han
  • Jang Hee Kim
  • Mi Sun Ahn
  • Yoon Ho Hwang
  • Hyun Woo Lee
  • Seok Yun Kang
  • Joon Seong Park
  • Jin-Hyuk Choi
  • Kwang Jae Lee
  • Seung Soo Sheen
  • Ho-Yeong Lim
Original Article

DOI: 10.1007/s10620-010-1280-8

Cite this article as:
Jeong, S.H., Han, J.H., Kim, J.H. et al. Dig Dis Sci (2011) 56: 131. doi:10.1007/s10620-010-1280-8
  • 223 Downloads

Abstract

Background

Platinum and 5-fluorouracil (5-FU)-based regimens have been used the most frequently in palliative chemotherapy for gastric cancer. The present study evaluated the prognostic significance of Bax, excision repair cross-complementation group 1 (ERCC1), and thymidylate synthase (TS) in advanced gastric cancer patients treated with 5-FU, leucovorin, and oxaliplatin (FOLFOX) palliative chemotherapy.

Methods

Seventy-two patients with metastatic or recurrent gastric cancer were treated with FOLFOX regimen. Pretreatment tumor biopsy specimens were analyzed for Bax, ERCC1, and TS expression by immunohistochemistry.

Results

High expression of Bax, ERCC1, and TS was observed in 31 (43%), 33 (46%), and 35 (49%) patients, respectively. The median overall survival (OS) of patients was 12 months. Low expression of Bax was associated with poor OS (median, 9 months vs. 18 months; 2-year, 10% vs. 48%; p = 0.0005) in univariate analysis, while expression of ERCC1 and TS was not correlated with patient outcome. In multivariate analysis, low expression of Bax was a significant independent predictor of poor OS (p = 0.028). Low expression of Bax was significantly associated with poor survival of patients with metastatic or recurrent gastric cancer treated with FOLFOX chemotherapy.

Conclusions

Immunohistochemical staining for Bax with pretreatment biopsy specimen may be useful in selecting FOLFOX regimen as a treatment option for advanced gastric cancer patients.

Keywords

Gastric cancer Bax Chemotherapy Prognosis 

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  • Seong Hyun Jeong
    • 1
  • Jae Ho Han
    • 2
  • Jang Hee Kim
    • 2
  • Mi Sun Ahn
    • 1
  • Yoon Ho Hwang
    • 1
  • Hyun Woo Lee
    • 1
  • Seok Yun Kang
    • 1
  • Joon Seong Park
    • 1
  • Jin-Hyuk Choi
    • 1
  • Kwang Jae Lee
    • 3
  • Seung Soo Sheen
    • 4
  • Ho-Yeong Lim
    • 5
  1. 1.Department of Hematology-OncologyAjou University School of MedicineSuwonRepublic of Korea
  2. 2.Department of PathologyAjou University School of MedicineSuwonRepublic of Korea
  3. 3.Department of GastroenterologyAjou University School of MedicineSuwonRepublic of Korea
  4. 4.Section of Clinical Epidemiology and Biostatistics in Clinical Trial CenterAjou University School of MedicineSuwonRepublic of Korea
  5. 5.Division of Hematology-Oncology, Department of Medicine, Samsung Medical CenterSungkyunkwan University School of MedicineSuwonRepublic of Korea

Personalised recommendations